Abstract
The randomized phase III OAK (a study of atezolizumab compared with docetaxel in participants with locally advanced or metastatic non-small-cell lung cancer [NSCLC] who have failed platinum-containing therapy) trial investigated the anti-programmed cell death ligand 1 (PD-L1) antibody atezolizumab for advanced or metastatic, previously treated, NSCLC. Atezolizumab significantly improved overall survival (OS) compared with docetaxel (hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.62-0.87; P = .0003; median OS, 13.8 vs. 9.6 months, respectively). Patient-reported outcomes (PROs) were collected to evaluate disease-related symptoms and health-related quality of life (HRQoL) to support the finding of a survival benefit. The first 850 patients were randomized to receive atezolizumab (1200 mg every 3 weeks) or docetaxel (75 mg/m2 every 3 weeks). PROs were collected on day 1 of cycle 1, day 1 of every subsequent cycle, and at the end-of-treatment visit for patients who completed ≥ 1 baseline and 1 postbaseline PRO assessment. The European Organisation for the Research and Treatment of Cancer QoL questionnaire and lung cancer module were used to assess PROs. Atezolizumab delayed the time to deterioration (TTD) in physical func...Continue Reading
Citations
Jan 25, 2020·PloS One·Stéphane Faury, Jérôme Foucaud
Feb 28, 2020·Patient Related Outcome Measures·Luigi CavannaElena Orlandi
Apr 2, 2020·BJU International·Sumanta K PalThomas Powles
May 28, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin ReckMark A Socinski
May 14, 2020·Expert Opinion on Drug Safety·Anna ManzoAlessandro Morabito
Feb 16, 2019·International Journal of Environmental Research and Public Health·Sabina Asensio-CuestaJuan M García-Gómez
Apr 9, 2020·Frontiers in Medicine·Thierry BerghmansAnne-Marie Dingemans
Jul 30, 2020·Current Oncology Reports·Nicolò Matteo Luca BattistiSupriya Mohile
May 28, 2019·Journal of Medical Economics·Ariane K KawataHuamao M Lin
Jun 7, 2020·Journal for Immunotherapy of Cancer·Ashley M HopkinsMichael J Sorich
Jul 18, 2020·Journal of Patient-reported Outcomes·Sara Colomer-LahigueraManuela Eicher
Jul 23, 2020·British Journal of Cancer·Fabio GomesAndrea Luciani
Jan 30, 2021·Technology in Cancer Research & Treatment·Wei ZhangXiaona Ren
Feb 5, 2021·JCO Oncology Practice·Laurie E McLouthKathryn E Weaver
Jan 14, 2021·Survey of Ophthalmology·Carmen Alba-Linero, Emilio Alba
Jan 25, 2021·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Martin ReckKenneth John O'Byrne
Mar 30, 2021·Clinical Lung Cancer·Edward B GaronNaiyer A Rizvi
Jul 21, 2021·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Amélie AnotaVirginie Westeel
Aug 26, 2021·Thoracic Cancer·Jun DuZhijie Wang
Aug 31, 2021·Frontiers in Pharmacology·Long MaZijiang Zhu
Aug 8, 2020·Bulletin du cancer·Elodie Coquan, Florence Joly
Oct 2, 2021·Bioengineered·Shizhen ZhengYuejun Du
Jan 12, 2022·Journal of Medical Internet Research·Ophélie WilczynskiHervé Lemasson